Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor
TR
By Tom Reyes · Markets Editor
Oct 30 07:50 ETSource: BioPharma Dive
From the source
Read at biopharmadive.comEarnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
